133 related articles for article (PubMed ID: 2942733)
1. Immunity and suppression in radiation- and radiation leukemia virus (RadLV)-induced leukemogenesis.
Yefenof E; Ben-David Y
Leuk Res; 1986; 10(7):797-801. PubMed ID: 2942733
[TBL] [Abstract][Full Text] [Related]
2. In vitro generation of cytotoxic lymphocytes against radiation- and radiation leukemia virus-induced tumors. III. Suppression of anti-tumor immunity in vitro by lymphocytes of mice undergoing radiation leukemia virus-induced leukemogenesis.
Yefenof E; Meidav A; Kedar E
J Exp Med; 1980 Dec; 152(6):1473-83. PubMed ID: 6256461
[TBL] [Abstract][Full Text] [Related]
3. High- and low-leukemogenic variants of the radiation leukemia virus (RadLV): immunogenic, suppressive and genetic properties in relation to leukemogenic activity.
Yefenof E; Ben David Y; Kotler M
Int J Cancer; 1984 Dec; 34(6):875-82. PubMed ID: 6439654
[TBL] [Abstract][Full Text] [Related]
4. Immunologic characteristics in relation to high and low leukemogenic activity of radiation leukemia virus variants. I. Cellular analysis of immunosuppression.
Haran-Ghera N; Ben-Yaakov M; Peled A
J Immunol; 1977 Feb; 118(2):600-6. PubMed ID: 320261
[TBL] [Abstract][Full Text] [Related]
5. High- and low-leukemogenic variants of the radiation leukemia virus (RadLV) differ in ability to induce tumor-specific immune suppression.
Yefenof E; Zilcha D
Int J Cancer; 1982 Sep; 30(3):355-9. PubMed ID: 6215365
[TBL] [Abstract][Full Text] [Related]
6. Suppressor and reactive lymphocytes in radiation leukemia virus (RadLV)-induced leukemogenesis.
Yefenof E; Ben-David Y
Cancer Immunol Immunother; 1983; 16(1):48-52. PubMed ID: 6227381
[TBL] [Abstract][Full Text] [Related]
7. Immunologic characteristics in relation to high and low leukemogenic activity of radiation leukemia virus variants. II. Analysis of the immune response.
Haran-Ghera N; Rubio N
J Immunol; 1977 Feb; 118(2):607-11. PubMed ID: 839072
[TBL] [Abstract][Full Text] [Related]
8. H-21-linked control of immunological resistance to viral leukemogenesis as a response to preleukemic cells.
Lonai P; Katz E; Peled A; Haran-Ghera N
Immunogenetics; 1981 Mar; 12(5-6):423-32. PubMed ID: 6260638
[TBL] [Abstract][Full Text] [Related]
9. T-cell lymphoma induction by radiation leukemia virus in athymic nude mice.
Ricciardi-Castagnoli P; Lieberman M; Finn O; Kaplan HS
J Exp Med; 1978 Nov; 148(5):1292-310. PubMed ID: 214507
[TBL] [Abstract][Full Text] [Related]
10. A highly leukemogenic radiation leukemia virus isolate is a thymotropic, immunosuppressive retrovirus with a unique RNA structure.
Ben David Y; Kotler M; Yefenof E
Int J Cancer; 1987 Apr; 39(4):492-7. PubMed ID: 2435664
[TBL] [Abstract][Full Text] [Related]
11. In vivo antigenic modification of tumor cells. III. Metastatic thymic lymphoma specifically infected by thymotropic retrovirus.
Iglehart JD; Weinhold KJ; Huper G; Thiel K; Bolognesi DP
J Natl Cancer Inst; 1981 Jul; 67(1):123-30. PubMed ID: 6265678
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of potential lymphoma-inducing cells in mice sensitive or resistant to lymphomagenesis by radiation leukemia virus variants.
Gokhman I; Peled A; Haran-Ghera N
Cancer Res; 1990 May; 50(9):2554-61. PubMed ID: 2158393
[TBL] [Abstract][Full Text] [Related]
13. Radiation leukemia virus-induced thymic lymphomas express a restricted repertoire of T-cell receptor V beta gene products.
Sen-Majumdar A; Weissman IL; Hansteen G; Marian J; Waller EK; Lieberman M
J Virol; 1994 Feb; 68(2):1165-72. PubMed ID: 8289345
[TBL] [Abstract][Full Text] [Related]
14. Target cells and thymus microenvironment in the pathogenesis of thymic lymphomas in C57BL/Ka mice.
Boniver J; Houben-Defresne MP; Goffinet G; Lenaerts P; Betz EH
Int J Radiat Oncol Biol Phys; 1985 Jan; 11(1):65-9. PubMed ID: 2981792
[TBL] [Abstract][Full Text] [Related]
15. Leukemogenic activity of B-ecotropic C-type retroviruses isolated from tumors induced by radiation leukemia virus (RadLV-RS) in C57BL/6 mice.
Legrand E; Guillemain B; Daculsi R; Laigret F
Int J Cancer; 1982 Aug; 30(2):241-7. PubMed ID: 6290400
[No Abstract] [Full Text] [Related]
16. Molecular basis of a unique tumor antigen of radiation leukemia virus-induced leukemia B6RV2: its relation to MuLV gp70 of xenotropic class.
Nakayama E; Uenaka A; DeLeo AB; Stockert E; Obata Y; Ueda R; Inui Y
J Immunol; 1986 May; 136(9):3502-7. PubMed ID: 3007622
[TBL] [Abstract][Full Text] [Related]
17. A role for elevated H-2 antigen expression in resistance to neoplasia caused by radiation-induced leukemia virus. Enhancement of effective tumor surveillance by killer lymphocytes.
Meruelo D
J Exp Med; 1979 Apr; 149(4):898-909. PubMed ID: 219130
[TBL] [Abstract][Full Text] [Related]
18. Characterization of RFM mouse T lymphocyte anti-oncofetal antigen immunity in apparent tumor-free, long-term survivors of sublethal X-irradiation by limiting dilution T lymphocyte cloning.
Rohrer JW; Culpepper C; Barsoum AL; Coggin JH
J Immunol; 1995 Mar; 154(5):2266-80. PubMed ID: 7868899
[TBL] [Abstract][Full Text] [Related]
19. Cell surface antigens of radiation leukemia virus-induced BALB/c leukemias defined by syngeneic cytotoxic T lymphocytes.
Kaneko Y; Oettgen HF; Obata Y; Nakayama E
Jpn J Cancer Res; 1989 Mar; 80(3):257-64. PubMed ID: 2542207
[TBL] [Abstract][Full Text] [Related]
20. Thymic lymphosarcomas obtained by X-rays in association with a weakly leukemogenic virus: cellular studies.
Legrand E; Galiay M; Astier-Gin T; Rollet C; Guillemain B; Duplan JF
Leuk Res; 1986; 10(7):791-5. PubMed ID: 3755485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
